Dr. John Cush RheumNow
2 years 8 months ago
"The speed of our forward motion is directly related to the velocity of the people around us."
- Seth Godin
https://t.co/9Abzj19Hp9 https://t.co/FxitvtO6sl
Dr. John Cush RheumNow
2 years 8 months ago
Metanalysis (60 RCTs; 20,418 SpA & PsA pts Rx 17 b/tsDMARDs) shows increased NonSerious infections (RR 1.15), @higher doses, longer Rx; mainly URI & ENT infxn, Signif for axSpA (RR 1.32), not PsA(RR 1.05). SIE were NOT increased https://t.co/Ab9Q9NRFu3 https://t.co/Gzoe3sRaXp
Dr. John Cush RheumNow
2 years 8 months ago
Swedish registry shows #PsA mortality risk ~11% (HR 1.11) higher than general pop., driven by comorbidity, esp in women (HR: 1.23) w/ longer Dz duration (HR: 1.18). Causes of death lead by CV Dz and malignancy. https://t.co/M6muM2UIkN https://t.co/az3kig9pBu
The role of thromboprophylaxis following total hip (THA) or total knee arthroplasty (TKA) is uncertain and consensus is lacking. A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding.
Dr. John Cush RheumNow
2 years 8 months ago
Here’s what will change my practice in Rheumatoid Arthritis
https://t.co/7L1QFSVzpe https://t.co/hmR3VOyKls
Dr. John Cush RheumNow
2 years 8 months ago
Race to the top: how high will treatment response rates in RA reach?
We have become used to the 60/40/20% rule for the outcome of ACR 20/50/70 for biologics and targeted synthetic DMARDs.
https://t.co/VJplM5GC31 https://t.co/gNsN3wX5tA
Dr. John Cush RheumNow
2 years 8 months ago
2023 EULAR #PMR referral recommendations:
1 Suspected/Dx pts: consider Rheum eval
2 Do full Hx+PE+Labs before referral
3 Refer Severe Sx PMR to rapid access
4 Defer steroids til rapid Rheum eval
5 Rheum Dx PMR w? +steroid response can be Rx by PCP https://t.co/42bL8BL3QJ https://t.co/ffpKoKXZJM
Dr. John Cush RheumNow
2 years 8 months ago
Withdraw DMARDS after remission?
Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer.
https://t.co/mQKhwv9wCt https://t.co/Q57t63vNKe
The window of opportunity concept in RA shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. A natural development of this was to reconsider the possibility of therapeutic interventions aimed at the prevention of rheumatoid arthritis.
Adult-onset Still’s disease is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis characterized by sustained fever, salmon-colored rash, and arthritis. The 2023 ACR convergence featured several abstracts spotlighting developments in understanding and managing this complex disease spectrum.
Dr. John Cush RheumNow
2 years 8 months ago
Calcineurin Inhibitors in Lupus Nephritis
Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/4CjJ8Ri3ym https://t.co/KUONVdMfBB
Dr. John Cush RheumNow
2 years 8 months ago
How do we Diversify Clinical Trials?
Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/fZ7kKfdRwP https://t.co/Non3X7zOxA
Dr. John Cush RheumNow
2 years 8 months ago
Is MTX Safe in the Elderly?
Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adult rheumatology positions matched! But 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled.
https://t.co/un9CbyYooL https://t.co/ilABvgr7bH

